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Background: Activating point mutations of GNAS at codon 201 have been detected in approximately
two thirds of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. Intraductal papillary
neoplasms of the bile ducts (IPNBs) morphologically resemble pancreatic IPMNs. This study sought to
assess the mutational status of GNAS at codon 201 in IPNBs.
Methods: Thirty-four patients were included. DNA from microdissected IPNBs was subjected to a
polymerase chain reaction and ligation method for the detection of GNAS mutations at codon 201 and of
KRAS mutations at codon 12. Mutational status was compared with clinical and pathologic data.
Results: The IPNBs had a median diameter of 3.5 cm and were located intrahepatically (n = 6),
extrahepatically (n = 13), both intra- and extrahepatically (n = 4) or in the gallbladder (intracystic papillary
neoplasms, n = 11). Most exhibited pancreatobiliary differentiation (n = 20), high-grade dysplasia (n = 26)
and an associated adenocarcinoma (n = 20). Analysis of GNAS codon 201 identified only one mutant
sample in a multifocal intestinal subtype intrahepatic IPNB with high-grade dysplasia. Six lesions har-
boured a KRAS codon 12 mutation.
Conclusions: GNAS codon 201 mutations are uncommon in IPNBs, by contrast with pancreatic IPMNs.
More comprehensive molecular profiling is needed to uncover the pathways involved in IPNB
development.
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Introduction
Intraductal papillary neoplasms of the bile duct (IPNBs) are
uncommon neoplasms arising in the biliary tree, which were first
described more than a century ago.1 In 1959, Caroli provided a
rigorous anatomical description of this entity.2 These neoplasms
can arise as either solitary or multifocal lesions within the biliary
tree; in the latter scenario they are termed in classical parlance
as ‘biliary papillomatosis’.3–6 Intraductal papillary neoplasms of
the bile duct show considerable morphologic similarities to
intraductal papillary mucinous neoplasms (IPMNs) of the pan-
creas. Both entities present with a prominent intraductal papillary
component within larger-diameter ducts, both are mucin-
producing, both harbour varying grades of dysplasia in the lining
epithelium, and both exhibit distinct patterns of differentiation,
such as intestinal and pancreatobiliary manifestations.3 Finally,
both IPMNs and IPNBs are bona fide precursor lesions of invasive
adenocarcinomas at their respective anatomic sites. In view of
these similarities, it has been proposed that IPNBs may be the
biliary counterpart of pancreatic IPMNs,7 although there are also
significant differences between IPMNs and IPNBs in incidence
of mucin hypersecretion, relative prevalence of different papilla*These authors contributed equally to this work.
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phenotypes and the frequency of high-grade dysplasia. Reports of
IPNBs in the Asian literature also cite aetiologic associations
(lithiasis, flukes) that differ from those of IPMNs.
Intraductal papillary neoplasms of the bile duct are predomi-
nantly diagnosed in the elderly population and show a slight male
predominance. Characteristically, patients suffer from abdominal
pain and recurrent cholangitis. The accompanying jaundice arises
as a result of the physical obstruction of bile outflow by the neo-
plasm itself or the viscous inspissated mucin.5 There are no
evident risk factors for IPNBs, although some studies have
reported an association with longstanding biliary inflammation.5,8
Because of the underlying risk for malignant transformation
to invasive adenocarcinomas (cholangiocarcinomas)5 and the
obstructive nature of the lesions, resection with clear margins is
the therapy of choice for IPNBs. Unfortunately, multifocal IPNBs
may recur even after apparently curative resection and, in rare
cases with diffuse intrahepatic disease, orthotopic liver transplan-
tation may be considered.4,6
Recently, Wu et al. analysed a large sample of 132 IPMNs,
including an admixture of tissue specimens and cyst fluid samples
for somatic alterations in 169 cancer-associated genes.9 They iden-
tified mutations of GNAS at codon 201 in two thirds (66%) of
analysed cases.9 GNAS, located on chromosome 20q, encodes for
the alpha subunit of a stimulatory G-protein, which activates a
cyclic 3′-5′-cyclic adenosine monophosphate (cAMP)-mediated
intracellular cascade, culminating in cellular proliferation and
growth.10 Although this ‘hotspot’ codon 201 mutation has been
previously described in endocrine neoplasms and, rarely, in col-
orectal carcinomas, this was the first report of involvement of this
oncogenic pathway in pancreatic neoplasia. The high prevalence
of GNASmutations in IPMNs has been confirmed by others,11 and
a subsequent study demonstrated that amongst cystic neoplasms
of the pancreas, GNAS mutations are restricted to IPMNs and are
not observed in solid pseudopapillary neoplasms or mucinous
cystic neoplasms.12 In light of the morphologic similarities
between IPMNs and IPNBs, and the shared embryologic origins
of the pancreas and biliary tree,13 the present authors investigated
the frequency of GNAS alterations in the latter using a sensitive
polymerase chain reaction (PCR)/ligation methodology. Notably,
the study found that GNAS codon 201 mutations are uncommon
in IPNBs, which suggests that alternative mechanisms for the
development of these neoplasms exist.
Materials and methods
Patients and tissues
The present study was approved by the Johns Hopkins University
Institutional Review Board and the review boards of collaborating
institutions, Memorial Sloan–Kettering Cancer Center, New York,
NY, and Emory University, Atlanta, GA, USA. Papillary lesions
located in the ampullary region were not included because it is
sometimes difficult to group them according to anatomical origin
(pancreatic vs. biliary vs. ampullary). The neoplasms were classi-
fied according to recent international guidelines.14 Reference slides
of all eligible cases were reviewed by pathologists at the partici-
pating institutes, who were experts in pancreatobiliary pathology
(RHH, AM, NVA, NK and DSK) to confirm the diagnosis of
IPNB, and corresponding formalin-fixed and paraffin-embedded
(FFPE) blocks for the most suitable specimens were selected for
subsequent molecular studies. A total of 34 IPNB specimens were
collated from the three collaborating institutions. Detailed infor-
mation about the patients included is shown in Table S1 (online).
Microdissection and DNA preparation
Twenty sections measuring 7 mm in thickness were cut from every
FFPE block in PCR clean conditions and mounted on plus-
charged glass slides, after which they were stained with hematoxy-
lin and eosin (H&E). The first and last sections were used as
references for needle microdissection. Thereafter, manual micro-
dissection of the neoplastic epithelium was performed using a
sterile needle on a stereoscopic zoom microscope SMZ1500
(Nikon Corp., Tokyo, Japan). Approximately 10 000 cells were
harvested from each lesion with an estimated tumour cellularity
of >80% and subjected to genomic DNA extraction using a
QIAamp DNA FFPE Tissue Kit (Qiagen, Inc., Valencia, CA, USA),
according to the manufacturer’s protocol.
PCR/ligation assay for the detection of GNAS and
KRAS mutations
Polymerase chain reaction products containing codon 12 of KRAS
and codon 201 of GNAS were amplified using the primers
described in Table S2. Each 10-ml PCR contained 200 template
molecules in 5 ml of 2¥ Phusion Flash PCR Master Mix (New
England Biolabs, Inc., Ipswich, MA, USA), and final concentra-
tions of 0.25 mM forward and 1.5 mM reverse primers. Note that
the mutant-specific probes in some cases included locked nucleic
acid residues (Exiqon Life Sciences A/S, Vedbaek, Denmark). The
following cycling conditions were used: 98 °C for 2 min; three
cycles of 98 °C for 10 s, 69 °C for 15 s, 72 °C for 15 s; three cycles
of 98 °C for 10 s, 66 °C for 15 s, 72 °C for 15 s; three cycles of 98 °C
for 10 s, 63 °C for 15 s, 72 °C for 15 s, and 41 cycles of 98 °C for
10 s and 60 °C for 60 s. Reactions were performed in at least
quadruplicate and each was evaluated independently. Five ml of a
solution containing 0.5 ml of Proteinase K, (18.8 mg/ml; Roche
AG, Basel, Switzerland) and 4.5 ml of dH2O was added to each well
and incubated at 60 °C for 30 min to inactivate the Phusion poly-
merase and then for 10 min at 98 °C to inactivate the Proteinase K.
The ligation assay was based on techniques described previ-
ously, using thermotolerant DNA ligases.15–18 Each 10-ml reaction
contained 2 ml of PCR product (unpurified), 1 ml of 10¥ Ampli-
gase buffer (Epicentre Biotechnologies, Inc., Madison, WI, USA),
0.5 ml of Ampligase (5 U/ml; Epicentre Biotechnologies, Inc.),
anchoring primer (final concentration 2 mM), wild-type specific
primer (final concentration 0.1 mM), and mutant-specific primer
(final concentration 0.025 mM). The sequences of these primers
are listed in Table S2. The following cycling conditions were used:
95 °C for 3 min, and 35 cycles of 95 °C for 10 s, 37 °C for 30 s and
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45 °C for 60 s. Five ml of each reaction was added to 5 ml of for-
mamide and the ligation products were separated on a 10% Urea-
Tris-Borate-EDTA gel (Life Technology, Inc., Grand Island, NY,
USA) and imaged with an Amersham-GE Typhoon instrument
(GE Healthcare Ltd, Waukesha, WI , USA).
Results
Clinical and pathologic characteristics of IPNBs
This study was conducted using archival IPNB cases collected
from three large hepatopancreatobiliary surgery centres in the
USA. The clinical and pathologic characteristics associated with
each of the 34 individual IPNB samples are detailed in Table S1
and a summary tabulation is presented in Table 1. The median age
of the 34 patients was 65 years (range: 26–88 years) and the sample
included 20 men and 14 women. The non-invasive component of
the IPNBs had a median diameter of 3.5 cm (range: 0.7–21.1 cm),
and the lesions were located throughout the biliary tree, including
in the intrahepatic ducts (n = 6), extrahepatic ducts (n = 13), both
intra- and extrahepatic ducts (n = 4) and in the gallbladder (n =
11). An associated invasive adenocarcinoma was observed in 20
cases. Tumour–node–metastasis (TNM) staging showed most of
the associated invasive cancers were T3 (n = 9) and had not yet
spread to local lymph nodes (n = 13). Upon histopathologic
examination, the non-invasive components uniformly exhibited
an intraductal papillary growth pattern (Fig. 1). Based on the
maximum grade of epithelial dysplasia, the lesions were classified
into 26 high-grade, five intermediate-grade and three low-grade
IPNBs.
Assessment of mutational status and
clinicopathologic correlation
A sensitive PCR/ligation method was used to detect GNAS and
KRAS mutations in DNA samples isolated from the 34 IPNBs.
Only one case harboured aGNAS codon 201mutation. TheGNAS
mutation was detected in a diffuse intrahepatic IPNB, of intestinal
subtype and exhibiting high-grade dysplasia. The 65-year-old
male patient in whom this neoplasm arose underwent a left lateral
hepatectomy and was alive without evident disease at 60 months
after resection.
KRASmutations were found in six patients.When the cohort of
patients withKRASmutations in their IPNBs were compared with
those without KRAS mutations for patient characteristics and
clinical and pathologic features (age, gender, location, subtype,
grade, maximum size, presence of invasive carcinoma and
outcome), no significant differences between the groups were
found (chi-squared test, P > 0.05).
Discussion
Invasive adenocarcinomas of the pancreas are postulated to arise
via two major dichotomous pathways involving non-invasive pre-
cursor lesions: pancreatic intraepithelial neoplasia (panIN), and
IPMNs.19 These two pathways are clinically, pathologically and
Table 1 Summary of clinical and pathologic data for 34 patients with
intraductal papillary neoplasms of the bile duct
Age, years,
median (range)
65 (54–76)
Gender, n Male 20
Female 14
Surgery, n Hepatectomy 7
Segmental bile duct
resection
3
Hepatectomy and
segmental bile duct
resection
5
Tumour
cholecystectomy
11
Orthotopic liver
transplantation
1
Pancreatoduodenectomy
(Whipple procedure)
7
Resection status,
n
0 28
1 2
Unknown 4
Location, n Intrahepatic bile ducts 6
Extrahepatic bile ducts 13
Intra- and extrahepatic
bile ducts
4
Gallbladder 11
Size, cm, median
(range)
3.5 (0.7–21.1)
Subtype, n Gastric 10
Intestinal 2
Pancreatobiliary 20
Oncocytic 2
Grade of
dysplasia, n
Low 3
Intermediate 5
High 26
Associated
invasive
cancer, n
Yes 20
No 14
Tumour stage T1 4
T2 6
T3 9
T4 1
N/A 14
Lymph node
metastases, n
N0 13
N1 3
NX 4
KRAS Mutation detected, n 6
GNAS Mutation detected, n 1
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genetically distinct. Analogous to the pancreas, two precursor
pathways have been pathologically identified in the biliary
tree, comprising non-papillary biliary intra-epithelial neoplasia
(bilIN) lesions, and IPBNs.20 Although molecular analyses of
either of the two biliary precursor lesions are limited, the available
information suggests underlying differences in terms of genetic
alterations, as well as clinical distinctions in the invasive carcino-
mas arising in the respective contexts.21–23
Emerging evidence suggests a number of similarities between
IPMNs and IPNBs. For example, Zen et al. analysed both entities
with respect to clinicopathologic features, expression of lineage-
associated proteins and prognostic parameters.7 They compared a
series of 32 IPNBs, including 22 with invasive cholangiocarcino-
mas, with a series of 31 pancreatic IPMNs (15 with associated
invasive cancer); 15 non-IPNB-associated cholangiocarcinomas
served as controls.7 The authors found that, similarly to those in
IPMN, invasive adenocarcinomas arising from IPNBs were often
of the mucinous type (five of 14, 35.7%). In addition, as seen in
the pancreas, three predominant epithelial subtypes were
observed in the biliary lesions, including gastric, intestinal and
pancreatobiliary phenotypes. Immunohistochemically, IPNBs
were characterized by the expression of apomucin MUC2, the
intestinal differentiation factor CDX2, and the intermediate fila-
ment cytokeratin CK20, all of which are features prevalent in
IPMNs, especially those of the intestinal subtype. Notably, these
expression patterns were uncommon in cholangioadenocarcino-
mas not associated with IPNBs. The authors concluded that
biliary papillary lesions may be regarded as the counterpart of
IPMNs of the pancreas.7
Thus far, only limited information exists on the prevalent
molecular alterations in IPNBs. Abraham et al. reported that
IPNBs can have low levels of microsatellite instability in up to a
third of cases, although these changes are not associated with loss
of hMLH1 function.24 Furthermore, the same group of investiga-
tors assessed a panel of IPNBs for somatic alterations of KRAS and
CTNNB1 hotspot regions, and found KRAS codon 12 mutations
in four of 14 (28.6%) IPNBs, whereas no CTNNB1 mutations
were detected.25 Table 2 provides an overview of the available
mutational data on IPNBs. The present study also suggests that
the rate of KRAS mutations in IPNBs is lower (six of 34, 17.6%)
than that previously reported in IPMNs (~80%),9 but comparable
with that described previously in IPNBs.25,26 Notably, a recent
genetically engineered mouse model of cholangiocarcinoma, gen-
erated by expression of mutantKRAS and Tp53 under an albumin
promoter during development, also demonstrated non-invasive
papillary lesions of the biliary tree histologically similar to the
cognate precursor lesions in humans, underscoring the potential
importance of mutant KRAS to the pathogenesis of some IPNBs.27
The availability of massively parallel sequencing technologies
has facilitated the identification of novel cancer-associated genes
in several cancer types.12,28–30 Using a massively parallel approach,
the present group and others identified activating mutations of
GNAS at codon 201 in about two thirds of IPMNs.9,11 Point muta-
tions of GNAS codon 227 have been reported in other tumour
types, although not in IPMNs. Mutations at both codons 201 and
227 constitutively activate the encoded G-protein alpha subunit.31
The functional impact of these activating mutations is to confer
cells with high adenyl cyclase activity and cAMP levels. GNAS
mutations have predominantly been observed in association
with endocrine disorders. For example, patients with McCune–
Albright syndrome harbour germline GNAS mutations and
present with a characteristic compendium of findings, including
acromegaly, fibrous dysplasia and café au lait discoloration.32–34
Approximately 40% of pituitary somatotroph (growth hormone
secreting) adenomas demonstrate GNAS mutations at either
codon 201 or codon 227.35 GNAS mutations are uncommon in
Figure 1 (a) Low- and (b) high-power photomicrographs obtained from an intraductal papillary neoplasms of the bile duct with high-grade
dysplasia. [Haematoxylin and eosin stain; original magnification (a) ¥10, (b) ¥20]
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epithelial malignancies, occurring only in minor subsets of col-
orectal, prostate and breast cancers, renal cell carcinomas and
small cell carcinomas of the lung, and these mutations are almost
always restricted to codon 201.36–40 In the hepatobiliary region,
GNAS mutations have been reported in only two of 245 (~1%)
hepatocellular carcinomas (HCCs) and in four of 164 (2.4%)
hepatocellular adenomas.41 Again, the mutations were all clustered
at codon 201 and the corresponding HCCs were associated with
an inflammatory infiltrate, postulated to reflect the activating of
underlying proinflammatory pathways [interleukin-6 and STAT-3
(signal transducer and activator of transcription 3)] by the con-
stitutively activated G-protein. Of note,GNASmutations have not
been identified in ‘usual’ pancreatic ductal adenocarcinomas
arising outwith the context of IPMNs.9,30
In the present study, GNAS mutations were detected only in a
single intrahepatic IPNB and the remaining 33 lesions were wild-
type at codon 201. These results are by stark contrast with the high
prevalence (66%) previously reported in non-invasive IPMNs by
Wu et al.9 In their study, GNAS mutations were observed at all
grades of epithelial dysplasia, suggesting it was an ‘early’ genetic
alteration. However, there was a tendency for subtype-specific
prevalence, with 100% of intestinal IPMNs and only ~50% of
gastric and pancreatobiliary IPMNs demonstrating GNAS codon
201 mutations. Interestingly, the single IPNB with a GNAS muta-
tion in the present series was of the intestinal subtype. Overall,
only two IPNBs showed intestinal differentiation in the present
series, and one of the two was positive for GNAS mutation. Thus,
the low prevalence of GNAS mutations in IPNBs may reflect the
low prevalence of intestinal differentiation in these neoplasms.
Nonetheless, it should be noted that ~50% of gastric and pancre-
atobiliary type IPMNs also harboured GNAS mutations,9 and all
of the 31 IPNBs comprising these two subtypes were wild-type,
suggesting a truly lower rate in the biliary counterparts.
There are several limitations to the present study. In this series,
a subset of the IPNBs presented as multifocal lesions (biliary
papillomatosis), but only the largest neoplastic foci were analysed.
The present authors have previously shown that IPMNs can be
heterogeneous with regard to GNAS mutations,9 and this study’s
failure to examine multiple synchronous lesions may have pro-
duced false negatives. The authors find this possibility less likely as
GNAS mutations would confer a growth advantage to the index
lesion and thus there is a high likelihood that the index lesion will
be the most prominent neoplastic focus in a multifocal IPNB.
Another caveat may be that the activating hotspot mutation in
IPNBs is not at GNAS codon 201, but, rather, at codon 227, which
was not examined in the current study. However, based on the
data that GNAS mutations in epithelial neoplasms (including
IPMNs) are always restricted to codon 201,9,35,42 the authors find
this possibility unlikely. Finally, the issue of assay sensitivity, which
is always a concern in a ‘negative’ study of this nature, should be
addressed. The PCR/ligation assay used herein can detect a single
mutant GNAS molecule amongst 200 wild-type templates (0.5%
lower limit of detection)9 and has been successfully used for iden-
tifying mutant GNAS in highly biologically heterogeneous pan-
creatic cyst fluid samples. Thus, the present authors consider it
quite unlikely that false negative results have been obtained using
microdissected tumour tissue (with neoplastic cellularity of
>80%).
In conclusion, GNAS codon 201 mutation, a newly discovered
‘mountain’ in the genetic landscape of IPMNs, is an uncommon
alteration in IPNBs, despite the morphologic similarities between
the two lesions arising at embryologically related sites. Addition-
ally, KRAS mutations are also less common in IPNBs than in
IPMNs. Based on the present series, it can be assumed that the
signalling pathways involved in the pathogenesis of IPNBs are
distinct from those in IPMNs. Larger, more comprehensive
sequencing studies should help to elucidate the genetic landscape
of IPNBs.
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